Latent Labs

Latent Labs announced the launch of Latent‑Y to researchers worldwide through the Latent Labs Platform, framing it as a lab-validated autonomous drug design agent and describing access mechanics including free daily access and on-demand credits for larger campaigns.

Latent Labs announced the upcoming launch of a Latent‑Y Research Tier, stating that approved researchers will receive broader access to run large-scale agentic protein design campaigns directly from the browser, with a launch event in London on July 15, 2026.

Latent Labs announced Latent‑Y as an autonomous AI agent for drug design, stating it can design zero-shot antibodies from text prompts and describing lab-validated outcomes and workflow compression (weeks of computational work into hours).

Latent Labs announced deployment results using NVIDIA Blackwell B300 GPUs in partnership contexts, describing more than 4x training speedups and over 60% faster inference relative to previous-generation chips for its generative models used in drug discovery pipelines.

Latent Labs announced Latent‑X2 as a frontier model for designing drug-like biologics without iteration, describing its use through the Latent Labs Platform and claims around low ex vivo immunogenicity. The announcement also mentions a strategic advisory board addition (Stefan Oschmann).

Latent Labs announced a multi-year strategic partnership with AWS, describing AWS as a preferred cloud provider for advanced AI training/inference capabilities and framing the partnership as a channel to scale access to its technology for biologists, pharma, and biotech innovators.

Latent Labs announced emerging from stealth with $50M total funding, describing a $40M Series A co-led by Radical Ventures and Sofinnova Partners (plus participation by Flying Fish and Isomer, and existing investors), and outlining its goal to accelerate generative protein design efforts for biotech and pharma partners.